by Dan Roberts Researchers have been able to halt (at least temporarily) choroidal neovascularization (CNV) with gene replacement therapy. This was done by single injections into the eyeballs of patients during a phase I clinical trial. Here is more detail, as reported on January 17, 2006 by Genetic Engineering News (www.genengnews.com): Clinical Trial on Gene [Read More]
